Eighteen clustered cases of meningococcal disease associated with B:2a:P1.5 strains doubled the annual incidence up to 4.3 ؋ 10 5 in Navarra, Spain, in 2007. Eleven percent of cases were fatalities, and 74% of cases were individuals 10 to 24 years old. This is the third cluster associated with this strain in northern Spain since 2001.
Neisseria meningitidis is an exclusively human pathogen causing sepsis and meningitis (13) . Its capsular polysaccharide is one of the most important virulence factors, defining the serogroup and being targeted for the currently available A, C, Y, and W-135 vaccines. N. meningitidis meningococci from serogroups B, C, Y, and W-135 express capsules composed of polysialic acid or sialic acid linked to glucose or galactose, while the capsules of meningococci from serogroup A are composed of N-acetyl mannosamine-1-phosphate. Meningococcal capsule switching appears to occur among sialic acidexpressing strains by allelic replacement of the sialic acid capsule polymerase. Since the genetic structure responsible for capsule expression in group A meningococci is different, homologous recombination with conversion of serogroup A strains to sialic acid capsule-expressing strains (by introduction of a sialic acid capsule biosynthetic operon) may be less likely (14) . This type of genetic event has been described to occur in both outbreak and nonoutbreak situations, and it might happen extraordinarily fast in vivo (16) .
In Spain, an increasing number of serogroup C meningococcal strains was observed in the second half of the 1990s (5), first associated with C:2b:P1.5,2 ST8 strains until 1999 (3) and since then with C:2a:P1.5 ST11 isolates. In response, a mass immunization campaign focusing on members of the population that were between 18 months and 19 years old was implemented, first with the polysaccharide AϩC vaccine in most of the country during 1997 and then with the new C conjugate polysaccharide vaccines introduced into the Spanish routine vaccination schedule in 2000 (4) . The efficacy of both interventions was quite high (6, 15) , but immune pressure might have the potential to select those organisms that have their capsules replaced (4, 8, 10) . Although the frequency of the capsular switching event is not known in nature, in a population immunized against meningococci from serogroup C, replacement of serogroup C 2a:P1.5 ST11 by serogroup B 2a:P1.5 ST11 meningococci might easily occur. In fact, since 2000 there have been two clusters associated with B:2a:P1.5 ST11 strains in northern Spain (7, 10, 12) .
The aim of this study was to analyze an increase in the incidence rate of meningococcal disease (MD) associated with B:2a:P1.5 strains from 2007 to January 2008 in Navarra, a region located in northern Spain that has 600,000 inhabitants.
The cases were assigned to Navarra when the patients were in this region during the incubation period, i.e., 2 to 10 days before the onset of illness (13) .
We analyzed all probable or confirmed cases of MD. A probable case was defined as a clinically compatible case in which gram-negative diplococci from a normally sterile site (e.g., cerebrospinal fluid, blood, or skin scrapings of purpuric lesions) were seen. A confirmed case was defined as a clinically compatible case with either isolation of N. meningitidis or detection of meningococcal DNA in a specimen from a normally sterile site.
For all MD cases, chemoprophylaxis was applied immediately for those who had come in close contact with the patient, both in the household and in school (11) .
In Navarra, the MD incidence rate ranged between 1.8 and 3. (Table 1) .
All isolates were sent to the Spanish Reference Laboratory (SRL) for serotyping and, when an isolate was not available, clinical samples were sent for real-time PCR diagnosis using the gene ctrA as a target. Cases were characterized by serotyping/serosubtyping with monoclonal antibodies (3) or genotyping/genosubtyping by porB and porA gene sequencing (1, 2). All B:2a:P1.5 strains isolated were analyzed by multilocus sequence typing (9) and pulsed-field gel electrophoresis after DNA digestion with BglII and compared with those strains isolated in sporadic cases and previous clusters in Spain.
B , two regions near Navarra. All isolates from Navarra showed closely related PTs representing closely related patterns of those PTs previously found in either sporadic or outbreak cases (Fig. 1) . However, those B:2a:P1.5 strains associated with previous clusters and also those isolated from sporadic cases look like homogeneous clones, showing some bands of difference with the strains associated with the cluster in Navarra. These isolates from Navarra might represent an evolutionary line evolving from the strains associated with previous clusters or they might have originated in an independent event representing a different line (Fig. 1) . The comparison of cases caused by B:2a:P1.5 (n ϭ 19) and cases caused by other B strains (n ϭ 25) over the period of 2006 to January 2008 in Navarra showed that infection with B:2a:P1.5 was most frequent among young people between 10 and 24 years old (74% versus 28%; P ϭ 0.005), and cases appeared exclusively in the capital city and in the northern part of the region (100% versus 72%; P ϭ 0.014). All cases caused by B:2a:P1.5 presented with sepsis or meningitis, while 24% of cases caused by other B strains presented with bacteremia (P ϭ 0.0289). Cases associated with B:2a:P1.5 strains showed a quite high but not statistically significant fatality rate (11% versus 0%; P ϭ 0.181). The frequency of associated secondary cases was also higher among B:2a:P1.5-associated cases than among other serogroup B-associated cases but without statistical significance (11% versus 0%; P ϭ 0.181).
Only three cases occurred among close contacts of primary cases. One was a case whose symptoms debuted before chemoprophylaxis was started. The other two had received chemoprophylaxis more than 10 days after the onset of symptoms, and the isolated strains had developed decreased susceptibility to rifampin (MIC, 0.125 mg/liter), which might explain the failure to eradicate nasopharyngeal carriage of the bacteria. However, new contacts with the bacteria also may have occurred in both cases. The results show the spread of these types of isolates in successive clusters of cases that affect mainly adolescents and young adults with severe clinical forms of MD and a high case fatality rate.
The emergence of isolation of these B:2a:P1.5 strains in Spain, coinciding with a progressive extension of meningococcal C vaccination, suggests that strong immunological pressure might be selecting these types of strains that evade the immune response produced by the vaccine. However, other explanations, such as the emergence of new, more virulent variants, could not be totally ruled out. No similar situation has been observed in other European countries using serogroup C conjugate vaccines (8) . Use of meningococcal C conjugate vaccines has been successful in Spain, with a dramatic reduction in the number of cases associated with this serogroup. However, we have to be alert to the appearance and spread of these types of meningococcal variants evading immune response.
